Author:
Toccafondi Alessandro,Mari Leonardo,Caraccia Umberto,Lapini Silvia,Dattolo Pietro,Capanni Claudia,Polvani Stefania,Lombardi Marco
Abstract
Introduction: Poor medication adherence in CKD patients is associated with high mortality and morbidity and can reach up to 80%. The most effective interventions to increase patients’ adherence to treatments are conducted by a multi-professional team and with the active participation of patients and their families. Narrative evidence-based medicine has been proved as a useful methodology in the care of chronic patients also in promoting their adherence to treatments.
Methods: Around 50-70% of CKD patients treated in our centre will follow clinical protocol based on a narrative medicine approach: (1) patients will be invited to write a brief history related to their experience with the CKD and treatments; (2) screening for depression (HADS; PHQ-9); (3) intervention of pharmaceutical counselling aimed to explore patients’ behaviours about taking their medications; (4) sharing of decision-making: the results of the narrative histories and of questionnaires will be discussed with the patients; (5) psychoeducational groups.
Results: The pilot phase of the project will last 6 months. During these months, patients will be monitored for biochemical (e.g. anemia) and anthropometric (e.g. blood pressure) parameters and depression. Medical visits or diagnostic tests missed by patients will also be recorded.
Conclusions: The development of an active role of patients in taking care of themselves is one of the main challenge of clinical nephrology. The present project aims to implement in the clinical routine a protocol based on the narrative medicine approach in which the biological, psychological and social needs of CKD patients are considered and discussed with them.
Reference22 articles.
1. 1. Hill NR, Fatoba ST, Oke JL,, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):e0158765.
2. 2. De Nicola L, Donfrancesco C, Minutolo R, et al. Epidemiologia della MRC in Italia: stato dell'arte e contributo dello studio CHARES. G Ital Nefrol. 2011;28:(4):401-7.
3. 3. Rosati A, Francesconi P, Profili F, Mennuti N. Prevalenza e rischi associati di mortalità ed eventi cerebro-cardio-vascolari in Toscana. Toscana Medica. Febbraio 2017.
4. 4. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19(6)1213-24.
5. The social cost of chronic kidney disease in Italy;Turchetti;Eur J Health Econ,2017